Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Carol Sartorius to Breast Neoplasms

This is a "connection" page, showing publications Carol Sartorius has written about Breast Neoplasms.

 
Connection Strength
  
 
 
6.366
  
  1. McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 09 02; 20(9):1443-1455.
    View in: PubMed
    Score: 0.372
  2. Ward AV, Anderson SM, Sartorius CA. Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment. J Mammary Gland Biol Neoplasia. 2021 12; 26(4):399-417.
    View in: PubMed
    Score: 0.354
  3. Horwitz KB, Sartorius CA. Response to: Progesterone and breast cancer pathogenesis. J Mol Endocrinol. 2021 01; 66(1):L1-L2.
    View in: PubMed
    Score: 0.332
  4. Horwitz KB, Sartorius CA. 90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future. J Mol Endocrinol. 2020 07; 65(1):T49-T63.
    View in: PubMed
    Score: 0.320
  5. Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 06 23; 22(1):68.
    View in: PubMed
    Score: 0.320
  6. McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ?-catenin dynamics in breast cancer cells. Oncogene. 2020 03; 39(12):2478-2492.
    View in: PubMed
    Score: 0.311
  7. Fettig LM, Sartorius CA. Phospho-PR Isoforms and Cancer Stem Cells: What Does the FOXO1 Say? Endocrinology. 2019 05 01; 160(5):1067-1068.
    View in: PubMed
    Score: 0.295
  8. Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 09 15; 77(18):4934-4946.
    View in: PubMed
    Score: 0.261
  9. Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 11 02; 36(44):6074-6084.
    View in: PubMed
    Score: 0.261
  10. Matthews SB, Sartorius CA. Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts. Horm Cancer. 2017 02; 8(1):4-15.
    View in: PubMed
    Score: 0.248
  11. Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015 Jun; 20(1-2):39-50.
    View in: PubMed
    Score: 0.228
  12. Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul; 34(28):3676-87.
    View in: PubMed
    Score: 0.215
  13. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49.
    View in: PubMed
    Score: 0.189
  14. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32.
    View in: PubMed
    Score: 0.185
  15. Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol. 2012 Jun 24; 357(1-2):71-9.
    View in: PubMed
    Score: 0.174
  16. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55.
    View in: PubMed
    Score: 0.161
  17. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab. 2008 Sep; 93(9):3295-8.
    View in: PubMed
    Score: 0.140
  18. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5774-9.
    View in: PubMed
    Score: 0.137
  19. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res. 2005 Nov 01; 65(21):9779-88.
    View in: PubMed
    Score: 0.116
  20. Sartorius CA, Shen T, Horwitz KB. Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat. 2003 Jun; 79(3):287-99.
    View in: PubMed
    Score: 0.098
  21. Semina SE, Alejo LH, Chopra S, Kansara NS, Kastrati I, Sartorius CA, Frasor J. Identification of a novel ER-NF?B-driven stem-like cell population associated with relapse of ER+?breast tumors. Breast Cancer Res. 2022 12 08; 24(1):88.
    View in: PubMed
    Score: 0.095
  22. Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 08 26; 8(34):eabm4358.
    View in: PubMed
    Score: 0.093
  23. Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022 04 19; 13(1):2011.
    View in: PubMed
    Score: 0.091
  24. Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 03; 61(3):359-371.
    View in: PubMed
    Score: 0.088
  25. Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021 02; 27(2):310-320.
    View in: PubMed
    Score: 0.083
  26. Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.
    View in: PubMed
    Score: 0.082
  27. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597.
    View in: PubMed
    Score: 0.082
  28. Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139.
    View in: PubMed
    Score: 0.081
  29. Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 02 27; 5(4).
    View in: PubMed
    Score: 0.078
  30. Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Res. 2019 03 06; 21(1):36.
    View in: PubMed
    Score: 0.073
  31. Wellberg EA, Johnson S, Finlay-Schultz J, Lewis AS, Terrell KL, Sartorius CA, Abel ED, Muller WJ, Anderson SM. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Res. 2016 12 20; 18(1):131.
    View in: PubMed
    Score: 0.063
  32. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 12; 35(4):547-573.
    View in: PubMed
    Score: 0.062
  33. Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM. Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. J Vis Exp. 2016 11 30; (117).
    View in: PubMed
    Score: 0.062
  34. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721.
    View in: PubMed
    Score: 0.062
  35. D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 11; 14(11):1054-1067.
    View in: PubMed
    Score: 0.061
  36. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 1994 Jul 15; 54(14):3868-77.
    View in: PubMed
    Score: 0.053
  37. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.
    View in: PubMed
    Score: 0.046
  38. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013 May 16; 32(20):2555-64.
    View in: PubMed
    Score: 0.046
  39. Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20.
    View in: PubMed
    Score: 0.046
  40. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkil? P, Perou CM, Horwitz KB. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2742-7.
    View in: PubMed
    Score: 0.044
  41. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010 Nov 01; 70(21):8927-36.
    View in: PubMed
    Score: 0.041
  42. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol. 2008; 630:94-111.
    View in: PubMed
    Score: 0.034
  43. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007 Nov 01; 67(21):10582-91.
    View in: PubMed
    Score: 0.033
  44. Harrell JC, Dye WW, Harvell DM, Sartorius CA, Horwitz KB. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis. 2008; 25(1):81-8.
    View in: PubMed
    Score: 0.033
  45. Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006 Sep 15; 66(18):9308-15.
    View in: PubMed
    Score: 0.031
  46. Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006 Feb; 147(2):700-13.
    View in: PubMed
    Score: 0.029
  47. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia. 2003 Jul; 8(3):257-68.
    View in: PubMed
    Score: 0.025
  48. Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).
    View in: PubMed
    Score: 0.018
  49. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem. 1993 May 05; 268(13):9262-6.
    View in: PubMed
    Score: 0.012
  50. Horwitz KB, Sartorius CA, Hovland AR, Jackson TA, Groshong SD, Tung L, Takimoto GS. Surprises with antiprogestins: novel mechanisms of progesterone receptor action. Ciba Found Symp. 1995; 191:235-49; discussion 250-3.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)